Meeting
2022 ASCO Genitourinary Cancers Symposium
Impact of concomitant cardiovascular therapies on efficacy and safety of relugolix verus leuprolide in men with advanced prostate cancer: Subgroup analysis from the phase 3 HERO study.
Authors
Neal D. Shore
Carolina Urologic Research Center, Myrtle Beach, SC
Neal D. Shore , Daniel J. George , Bryan Allyn Mehlhaff , Michael Cookson , Daniel Saltzstein , Ronald F. Tutrone , Bruce Brown , Sophia Lu , Jina Lee , Sarah Hanson , Fred Saad
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03085095
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 101)
DOI
10.1200/JCO.2022.40.6_suppl.101
Abstract #
101
Poster Bd #
E11
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Efficacy and safety of relugolix in men with advanced prostate cancer based on baseline body mass index (BMI): A subgroup analysis from the randomized, phase 3 HERO study versus leuprolide (LEU).
First Author: Fred Saad
Poster
2022 ASCO Genitourinary Cancers Symposium
Efficacy and safety of relugolix in black men with advanced prostate cancer: A subgroup analysis from the randomized, phase 3 HERO study versus leuprolide.
First Author: Daniel J. George
Poster
2024 ASCO Genitourinary Cancers Symposium
Testosterone suppression and recovery in patients with advanced prostate cancer treated with intermittent androgen deprivation therapy (iADT) with relugolix.
First Author: Patrick Campbell
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world experience on tolerability and safety of relugolix combined with androgen signaling inhibitors in patients with advanced prostate cancer.
First Author: Jian Guan